Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401720 | 1.00 | DGKA (0.61) | DGKALMNAMAPTPAMCES2 | |
| SCHEMBL2181366 | 1.00 | DGKA (0.61) | DGKALMNAMAPTPAMCES2 | |
| SCHEMBL14421969 | 1.00 | DGKA (0.61) | DGKALMNAMAPTPAMCES2 | |
| SCHEMBL2182481 | 1.00 | DGKA (0.61) | DGKALMNAMAPTPAMCES2 | |
| SCHEMBL27469025 | 0.98 | DGKA (0.59) | DGKALMNAMAPTPAMCES2 | |
| SCHEMBL667664 | 0.98 | DGKA (0.59) | DGKALMNAMAPTPAMCES2 | |
| SCHEMBL5139559 | 0.98 | — | — | |
| SCHEMBL19358157 | 0.96 | DGKA (0.57) | DGKALMNAMAPTPAMCES2 | |
| SCHEMBL5050853 | 0.90 | — | — | |
| SCHEMBL2234093 | 0.88 | TERT (0.61) | LMNAMAPTPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011084850-A1 | PRODRUGS FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISEASE | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | DGKA 2298/4885LMNA 1728/4885MAPT 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.